Saxagliptin (BMS-477118)

Catalog No. A11109

Saxagliptin (BMS-477118)是一种新型二肽基肽酶4(DPP-4)抑制剂,IC50为50 nM。
  • OHE El-Shoubashy, .et al. Comparative study of HPLC-DAD and HPTLC for the simultaneous determination of a new multitarget antidiabetic ternary mixture in combined tablets, JPC, 2020, 33, 59-70
  • Sato T, .et al. DPP8 is a novel therapeutic target for multiple myeloma, Sci Rep, 2019, Dec 2;9(1):18094 PMID: 31792328
  • Chintan N. Koyani, .et al. Saxagliptin but Not Sitagliptin Inhibits CaMKII and PKC via DPP9 Inhibition in Cardiomyocytes, Front Physiol, 2018, 9: 1622 PMID: 30487758
  • Koyani CN, .et al. Dipeptidyl peptidase-4 independent cardiac dysfunction links saxagliptin to heart failure, Biochem Pharmacol, 2016, Dec 1;145:64-80 PMID: 28859968
Catalog Num A11109
M. Wt 315.4
Formula C18H25N3O2
Purity >98%
Storage at -20°C 3 years Powder
CAS No. 361442-04-8
Synonyms BMS-477118,Onglyza
SMILES C1[C@@H]2C[C@@H]2N([C@@H]1C#N)C(=O)[C@H](C34CC5CC(C3)CC(C5)(C4)O)N
Saxagliptin (BMS-477118)是一种新型二肽基肽酶4(DPP-4)抑制剂,IC50为50 nM。
Targets
DPP-4
26 nM
In vitro (25°C) DMSO 62 mg/mL (196.57 mM)
Water 62 mg/mL (196.57 mM)
Ethanol 24 mg/mL (76.09 mM)
In vivo Saline 28 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
0.1 mM 31.71 mL 158.53 mL 317.06 mL
0.5 mM 6.34 mL 31.71 mL 63.41 mL
1 mM 3.17 mL 15.85 mL 31.71 mL
5 mM 0.63 mL 3.17 mL 6.34 mL

*The above data is based on the productmolecular weight 315.4 . Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.